Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00284
|
|||||
| Drug Name |
Daunorubicin
|
|||||
| Synonyms |
(+)-Daunomycin; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Acetyladriamycin; Anthracyline; Antibiotics from Streptomyces coeruleorubidus; Cerubidin; Cerubidine; DAUNORUBICIN HCL; DM1; Daunamycin; Daunarubicinum; Dauno-Rubidomycine; DaunoXome; DaunoXome (TN); Daunoblastin; Daunoblastine; Daunomycin; Daunorrubicina; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin [INN:BAN]; Daunorubicin, Hydrochloride; Daunorubicine; Daunorubicinum; Daunorubicinum [INN-Latin]; FI 6339; FI6339; Leukaemomycin C; RP 13057; Rubidomycin; Rubomycin; Rubomycin C; VS-103
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute myeloid leukemia [ICD11: 2A60] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H29NO10
|
|||||
| Canonical SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
|
|||||
| InChI |
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
|
|||||
| InChIKey |
STQGQHZAVUOBTE-VGBVRHCVSA-N
|
|||||
| CAS Number |
CAS 20830-81-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 527.5 | Topological Polar Surface Area | 186 | ||
| Heavy Atom Count | 38 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 11 | |||
| XLogP |
1.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103477782
, 104066339
, 104307942
, 11114094
, 117393873
, 124766118
, 124886869
, 124886870
, 124886871
, 125299287
, 126663226
, 127301039
, 127301040
, 127301041
, 14763056
, 15481415
, 24769892
, 26697306
, 26701813
, 26704223
, 26715132
, 26718351
, 26718779
, 29215022
, 34672588
, 46508433
, 47440436
, 47736668
, 48110630
, 48415843
, 49699346
, 49855159
, 50070917
, 50104250
, 5016
, 53788227
, 56465013
, 57288764
, 57310919
, 596008
, 74382025
, 74462219
, 7887073
, 7979028
, 8171488
, 85788867
, 866161
, 92307396
, 92308820
, 96024474
|
|||||
| ChEBI ID |
ChEBI:41977
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
| MRP6 | Transporter Info | Multidrug resistance-associated protein 6 | Substrate | [4] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | BCRP | Transporter Info | Km = 2.5 microM | Spodoptera frugiperda (Sf9) cells-BCRP | [2] | |
| MRP1 | Transporter Info | Km = 1.4 microM | Human small cell lung cancer cells | [6] | ||
| P-GP | Transporter Info | Km = 1.74 microM | High five cells-MDR1 | [7] | ||
| References | ||||||
| 1 | Daunorubicin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. | |||||
| 3 | Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. | |||||
| 4 | Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. | |||||
| 5 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 6 | Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol. 1994 Sep 15;48(6):1129-36. | |||||
| 7 | Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.